Showing 1 – 20 of 423
Relevance | Newest | Oldest |
  • JAMA January 24, 2017

    Figure 6: County-Level Mortality From Pancreatic Cancer

    A, Age-standardized mortality rate for both sexes combined in 2014. B, Relative percent change in the age-standardized mortality rate for both sexes combined between 1980 and 2014. In panels A, and B, the color scale is truncated at approximately the first and 99th percentiles as indicated by the range given in the color scale. C, Age-standardized mortality rate in 1980, 1990, 2000, and 2014. The bottom border, middle line, and top border of the boxes indicate the 25th, 50th, and 75th percentiles, respectively, across all counties; whiskers, the full range across counties; and circles, the national-level rate.
  • Trends and Patterns of Disparities in Cancer Mortality Among US Counties, 1980-2014

    Abstract Full Text
    free access has multimedia
    JAMA. 2017; 317(4):388-406. doi: 10.1001/jama.2016.20324

    This cancer epidemiology study uses National Center for Health Statistics population data to estimate trends in age-standardized cancer mortality rates by US county between 1980 and 2014.

  • Pancreatic Cancer Blocked From Invading Nearby Nerves

    Abstract Full Text
    JAMA. 2017; 317(1):17-17. doi: 10.1001/jama.2016.19837
  • Study Links Periodontal Disease Bacteria to Pancreatic Cancer Risk

    Abstract Full Text
    JAMA. 2016; 315(24):2653-2654. doi: 10.1001/jama.2016.6295

    This Medical News story discusses research that identifies a positive association between oral microbiome dysbiosis and pancreatic cancer.

  • Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial

    Abstract Full Text
    free access
    JAMA. 2016; 315(17):1844-1853. doi: 10.1001/jama.2016.4324

    This randomized trial compares the effects of induction gemcitabine with vs without erlotinib in patients with locally advanced pancreatic cancer and, among those responsive to treatment, compares the effects of chemotherapy with vs without radiation.

  • Optimizing Treatment for Locally Advanced Pancreas Cancer: Progress but No Precision

    Abstract Full Text
    JAMA. 2016; 315(17):1837-1838. doi: 10.1001/jama.2016.4284
  • New Pancreatic Cancer Drug

    Abstract Full Text
    JAMA. 2015; 314(21):2227-2227. doi: 10.1001/jama.2015.16166
  • Early Signs of Pancreatic Cancer

    Abstract Full Text
    JAMA. 2014; 312(17):1729-1729. doi: 10.1001/jama.2014.14889
  • MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer

    Abstract Full Text
    free access
    JAMA. 2014; 311(4):392-404. doi: 10.1001/jama.2013.284664

    Schultz and coauthors report preliminary data on microRNA biomarkers in whole blood for detection of pancreatic cancer. In an accompanying Editorial, Buchsbaum and Croce discuss whether detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer.

  • Will Detection of MicroRNA Biomarkers in Blood Improve the Diagnosis and Survival of Patients With Pancreatic Cancer?

    Abstract Full Text
    JAMA. 2014; 311(4):363-365. doi: 10.1001/jama.2013.284665
  • Adjuvant Chemotherapy With Gemcitabine and Long-term Outcomes Among Patients With Resected Pancreatic Cancer: The CONKO-001 Randomized Trial

    Abstract Full Text
    free access
    JAMA. 2013; 310(14):1473-1481. doi: 10.1001/jama.2013.279201

    To analyze whether previously reported improvement in disease-free survival with adjuvant gemcitabine therapy translates into improved overall survival, Oettle and coauthors conducted a multicenter, open-label, phase 3 randomized trial to evaluate the efficacy and toxicity of gemcitabine in patients with pancreatic cancer after complete tumor resection.

  • JAMA October 13, 2010

    Figure 1: Survival Probability for Patients With Advanced Cancer and Matched Cancer-Free Controls by Cancer Site

    For patients with advanced cancer, the median overall survival following case follow-up start date for lung cancer was 5 months; for colorectal cancer, 8 months; for pancreatic cancer, 4 months; for gastroesophageal cancer, 4 months; and for breast cancer, 16 months. The overall survival at 5 years for each cancer was 3%, 5%, 3%, 2%, and 16%, respectively. Each cancer-free control was matched to a case with the specific cancer diagnosis by age, sex, race/ethnicity, and Surveillance, Epidemiology, and End Results tumor registry. For the cancer-free controls, the median overall survival was not reached and the overall survival at 5 years was 82% for lung cancer, 80% for colorectal cancer, 81% for pancreatic cancer, 81% for gastroesophageal cancer, and 85% for breast cancer.
  • Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial

    Abstract Full Text
    free access
    JAMA. 2010; 304(10):1073-1081. doi: 10.1001/jama.2010.1275
  • Refinement of Adjuvant Therapy for Pancreatic Cancer

    Abstract Full Text
    JAMA. 2010; 304(10):1124-1125. doi: 10.1001/jama.2010.1302
  • Pancreatic Cancer

    Abstract Full Text
    JAMA. 2010; 304(10):1140-1140. doi: 10.1001/jama.304.10.1140
  • JAMA September 8, 2010

    Figure 1: ESPAC-3 Study Flow

    ESPAC indicates European Study Group for Pancreatic Cancer.aDiscontinued in June 2003 owing to statistical evidence for survival benefit attributable to adjuvant chemotherapy.bPrincipal investigator at research site retired from practice with no replacement.
  • Risk of Pancreatic Cancer in Families With Lynch Syndrome

    Abstract Full Text
    free access
    JAMA. 2009; 302(16):1790-1795. doi: 10.1001/jama.2009.1529
  • JAMA October 28, 2009

    Figure: Age-Specific Cumulative Risk of Pancreatic Cancer in Families With Pathogenic Mutations in MLH1, MSH2, or MSH6 Genes

    MMR carriers indicates families with mismatch repair gene mutation carriers (MLH1, MSH2, or MSH6); SEER, Surveillance, Epidemiology, and End Results. The penetrance curves were generated by plotting the age-specific cumulative risks of pancreatic cancer (Table 3) for a set of discrete ages from 20 to 70 years at 5-year intervals and then applying a smoothing spline function. The 95% confidence intervals (error bars) corresponding with the age-specific cumulative risk of pancreatic cancer for MMR carrier families were also plotted at 50 and 70 years. Population estimates of age-specific cumulative risks of pancreatic cancer are given by pancreatic cancer incidence rates reported in 1992-2005 SEER 13 (http://seer.cancer.gov).
  • JAMA June 24, 2009

    Figure 2: Associations With Risk of Pancreatic Cancer Among All Study Participants and Among Those Without a History of Diabetes

    The odds ratios and 95% confidence intervals (CIs) were obtained from logistic regression analysis with adjustment for age, sex, race, smoking status, alcohol consumption, history of diabetes, and family history of cancer.
  • Body Mass Index and Risk, Age of Onset, and Survival in Patients With Pancreatic Cancer

    Abstract Full Text
    free access
    JAMA. 2009; 301(24):2553-2562. doi: 10.1001/jama.2009.886